Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA) market, which reached nearly $2 billion in 2008 in the United States, France, Germany, Italy, Spain and United Kingdom. These agents have revolutionized the treatment of niche immune diseases known as the seronegative SpAs - ankylosing spondylitis, psoriatic arthritis, and reactive arthritis - and ushered in a period of strong sales growth in these markets.
The new Spectrum report entitled Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases finds that the need for efficacious therapies to treat SpAs resulted in strong adoption of TNF-alpha inhibitors and, in turn, has proven to be a source of additional sales for blockbuster agents such as Enbrel, Remicade and Humira. In addition, physicians' familiarity with TNF-alpha inhibitors is expected to aid in the uptake of the newest agent in this drug class, Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe's Simponi, which was approved in late April by the Food and Drug Administration (FDA) for the treatment of psoriatic arthritis and ankylosing spondylitis.
"Simponi's advantages over existing TNF-alpha inhibitors are appealing to rheumatologists, and we forecast strong adoption for this agent," said Decision Resources Analyst Jennifer Moniz Carpenter, M.B.A. "However the success of the TNF-alpha inhibitors has reduced the level of perceived need in these markets, and in order to be successful in this space, other companies developing agents for SpAs - including Bristol-Myers Squibb, Novartis and Celgene - will need to fully understand the dynamics and remaining needs of the individual indications that it comprises."
According to the report, the SpA market will continue to grow over the next five to ten years, although the sales picture across the three diseases will vary widely as the reactive arthritis drug sector is markedly different than the sectors for the other two diseases. While the combined market in 2008 for ankylosing spondylitis and psoriatic arthritis was approximately $1.8 billion, the reactive arthritis drug market in that year was only $3 million, and TNF-alpha inhibitors have not been widely incorporated into medical practice for this exceedingly rare disease.
About Spectrum's Strategic Overviews
Spectrum's Strategic Overviews are comprehensive examinations of dynamic biopharmaceutical markets and industry issues. Primary research, data analysis, thought-leader consultation and the expertise of the industry-savvy Spectrum staff drive reports that offer breadth of coverage along with depth of strategic insight.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
email@example.com; or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/